A trial comparing two combinations of chemotherapy for clear cell ovarian cancer (CCC1)

Cancer type:

Ovarian cancer

Status:

Results

Phase:

Phase 3

This trial compared paclitaxel and carboplatin with irinotecan and cisplatin for clear cell cancer, a rare form of ovarian cancer. Cancer Research UK supported this trial.

More about this trial

Doctors usually treat ovarian cancer with surgery and then chemotherapy. They often use the chemotherapy drugs paclitaxel (Taxol) and carboplatin. But these drugs don’t always work very well for clear cell ovarian cancer.

Doctors hoped a combination of irinotecan and cisplatin would work better.

The aims of this trial were to find:

  • how well irinotecan and cisplatin worked for clear cell ovarian cancer
  • more about the side effects of this combination of treatment 

Summary of results

The trial team found that irinotecan and cisplatin didn’t work any better than paclitaxel and carboplatin for clear cell ovarian cancer.

This was an international phase 3 trial. It was a randomised trial.

667 women took part. The team was able to look at the results for 619 women.

  • 305 women had paclitaxel and carboplatin
  • 314 women had irinotecan and cisplatin

Diagram showing CCC1 randomisation results

After 2 years the team looked at the total number of women in each group who were still alive. They found this was:

  • 247 women who had paclitaxel and carboplatin
  • 248 women who had irinotecan and cisplatin

They also looked at how many women had no sign of cancer. They found this was:

  • 226 women who had paclitaxel and carboplatin
  • 222 women who had irinotecan and cisplatin

The most severe side effects of paclitaxel and carboplatin were:

  • a drop in blood cells
  • nerve damage (peripheral neuropathy)
  • joint pain

The most severe side effects of irinotecan and cisplatin were:

  • loss of appetite
  • diarrhoea
  • feeling or being sick
  • high temperature and low white blood cells (febrile neutropenia)

The trial team concluded that irinotecan and cisplatin isn’t any better than paclitaxel and carboplatin as a treatment for clear cell ovarian cancer. 

We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr John Green

Supported by

Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
NHS Greater Glasgow & Clyde 
University of Glasgow

Other information

This is Cancer Research UK trial number CRUK/07/029.

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

1708

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Wendy took part in a new trial studying the possible side effect of hearing loss

A picture of Wendy

"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page